# US 9,724,313 B2 · Pharmaceutical composition for use in medical and veterinary ophthalmology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,724,313 B2
- Document ID: US9724313B2
- Status: Granted
- Kind: B2
- Application number: 13/315,397
- Filed: 2011-12-09
- Published: 2012-04-19
- Granted: 2017-08-08
- Earliest claimed: 2009-06-10
- Assignees: Mitotech SA
- Applicants: Maxim V. Skulachev
- Inventors: Maxim V. Skulachev
- Web page: https://patentgrep.com/patent/US9724313B2

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- C09B 69/001: {Dyes containing an onium group attached to the dye skeleton via a bridge}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.

## Claims

### Claim 1

A pharmaceutical formulation for treatment or prophylaxis of eye pathology, comprising:
(a) from 1 nm to 25000 nm of a mitochondria-addressed antioxidant comprising:
(b) from 0.01% to 0.2% of a lipophilic, cationic concentration stabilizer that stabilizes a concentration of the mitochondria-addressed antioxidant by preventing reversible and irreversible absorption of the antioxidant to walls of a vial containing the pharmaceutical composition, the stabilizer comprising a benzalkonium salt, berberine, palmatine, tetraphenylphosphonium, tetrabutyl ammonium, or combinations thereof; and
(c) from 0.001% to 1% of a prolongator comprising a disaccharide, a trisaccharide, a polysaccharide, methylcellulose, hydroxyethylcellulose, hydroxypropyl-methylcellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, carboxyvinyl polymer, polyvinyl ethanol, polyvinylpyrrolidone, macrogol, or combinations thereof.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the mitochondria-addressed antioxidant is SkQ1-Br, SkQ1-C1, or SkQ12-SO4.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising a physiologically acceptable pH buffer comprising a phosphate buffer, an acetate buffer, a borate buffer, a carbonate buffer, a citrate buffer, a Tris buffer, a glutamine buffer, an epsilon-aminocaproic acid buffer, or combinations thereof.

### Claim 4 (depends on 1)

The pharmaceutical formulation of claim claim 1, wherein the water soluble cellulose derivative comprises methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, or combinations thereof.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising an isotonic component comprising sodium chloride, calcium chloride, glycerol, mannitol, sorbitol, boric acid, glucose, propylene glycol, or combinations thereof.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising an active ingredient different than the mitochondria-addressed antioxidant, the additional active ingredient being an antioxidant, an antiseptic, an astringent, a cautery, a resorbent, a hyposensitizer, an anti-biotic, an anti-inflammatory preparation, an antibacterial, a sulfanilamide preparation, an antiviral preparation, a non-specific anti-inflammatory, a reparative preparation, a local anesthetic, a systemic ophthalmologic preparation, an anti-cataract preparation, a hypotensive anti-glaucoma medical preparation, a cholinomimetic preparation, an anticholinesterase preparation, a sympathomimetic, an adrenergic preparation, an antiadrenergic preparation, a beta-adrenergic blocker, a prostaglandin, a carbonic anhydrase inhibitor, a mydriatic, a vitamin, and a vitamin analog, a natural cornea moisture restorer, or combinations thereof.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1 comprising, per 5 ml of solution:
about 770 ng SkQ1 bromide;
about 4.4 mg sodium dihydrophosphate;
about 4.7 mg sodium hydrogen phosphate dodecahydrate;
about 10 mg hydroxypropylmethylcellulose;
about 5 μg benzalkonium chloride;
about 45 mg sodium chloride; and
purified water to 5.0 ml.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the lipophilic, cationic concentration stabilizer comprises benzalkonium chloride, benzethonium chloride, berberine, palmatine, tertraphenylphosphonium, tertrabutyl, ammonium, or combinations thereof.